ABBISKO CAYMAN DL-00001 Total Liabilities
ABBISKO CAYMAN DL-00001 total liabilities. Based on the latest financial reports, ABBISKO CAYMAN DL-00001 (8ZD) has total liabilities worth €430.22 Million EUR (≈ $502.97 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of ABBISKO CAYMAN DL-00001 to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ABBISKO CAYMAN DL-00001 (2021–2025)
Total liabilities of ABBISKO CAYMAN DL-00001 from 2021 to 2025. This chart illustrates how ABBISKO CAYMAN DL-00001's total liabilities have evolved over time, based on quarterly financial data.
ABBISKO CAYMAN DL-00001 Competitors by Total Liabilities
The table below lists competitors of ABBISKO CAYMAN DL-00001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Gongdong Medical Technology Co Ltd
SHG:605369
|
China | CN¥451.25 Million |
|
Wangli Security & Surveillance Product Co. Ltd
SHG:605268
|
China | CN¥2.69 Billion |
|
Orthopediatrics Corp
NASDAQ:KIDS
|
USA | $167.77 Million |
|
NETGEAR Inc
NASDAQ:NTGR
|
USA | $332.28 Million |
|
Rio2 Ltd
V:RIO
|
Canada | CA$87.09 Million |
|
Zhejiang Netsun Co Ltd
SHE:002095
|
China | CN¥411.65 Million |
|
Guangdong Enpack Packaging Co Ltd
SHE:002846
|
China | CN¥2.37 Billion |
|
Sido Muncul PT
JK:SIDO
|
Indonesia | Rp265.52 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ABBISKO CAYMAN DL-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 8ZD asset base.
Liquidity & Leverage Metrics
ABBISKO CAYMAN DL-00001 Total Liabilities Ratios Explained
ABBISKO CAYMAN DL-00001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABBISKO CAYMAN DL-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABBISKO CAYMAN DL-00001 (2021–2025)
The table below shows the annual total liabilities of ABBISKO CAYMAN DL-00001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €430.22 Million ≈ $502.97 Million |
+189.30% |
| 2024-12-31 | €148.71 Million ≈ $173.86 Million |
+10.75% |
| 2023-12-31 | €134.28 Million ≈ $156.99 Million |
-6.20% |
| 2022-12-31 | €143.16 Million ≈ $167.37 Million |
+20.83% |
| 2021-12-31 | €118.48 Million ≈ $138.52 Million |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more